Cervical cancer screening is an essential component of preventive healthcare for women and anyone who has a cervix. Screening can identify high-risk human papillomavirus, commonly called HPV, and detect cervical cell changes before they progress to cancer. Because these early changes usually cause no symptoms, attending screening at the recommended interval remains important even when a person feels completely healthy.
Ontario’s cervical screening process has recently changed. Since March 2025, HPV testing has replaced the traditional Pap test as the primary cervical screening test in the Ontario Cervical Screening Program. Although many patients still use the familiar term “Pap test,” the current test first looks for high-risk HPV. Cytology, which examines cervical cells, may then be completed automatically when certain HPV results are found.
Women who are uncertain about their eligibility, previous results or next screening date can discuss their history with a family physician in Etobicoke. Patients without an established primary care provider may also contact a walk-in clinic in Etobicoke to ask whether cervical screening, result review or an appropriate referral is available.
Key Points to Remember
- Ontario now uses HPV testing as its primary cervical screening method.
- Most eligible people begin routine screening at age 25.
- A negative HPV result generally means screening can be repeated in five years.
- An HPV-positive result does not mean that cervical cancer is present.
- HPV vaccination reduces risk but does not eliminate the need for screening.
- Unusual bleeding, pelvic pain or abnormal vaginal discharge requires medical assessment rather than waiting for routine screening.
Understanding Pap Tests, HPV Tests and Cervical Cancer
The cervix is the lower, narrow portion of the uterus that connects with the vagina. Cervical cancer typically develops gradually after abnormal cells appear in cervical tissue. These changes may remain precancerous for years, creating an opportunity for screening, monitoring and treatment before invasive cancer develops. Regular screening is therefore designed to prevent cancer, not simply to diagnose it after symptoms appear.
A Pap test, also known as cervical cytology, examines cells collected from the surface of the cervix. A laboratory specialist assesses the sample for abnormal cellular changes. Pap testing was Ontario’s primary cervical screening method for many years. However, a normal Pap result could not directly establish whether a high-risk HPV infection was present, and cervical abnormalities could sometimes develop between screening appointments.
An HPV test examines the cervical sample for high-risk types of human papillomavirus. HPV includes more than 200 related viruses, approximately 40 of which can affect the genital area, mouth or throat. Most infections do not produce symptoms. Persistent infection with a high-risk HPV type can cause abnormal cervical cells and, in a small proportion of cases, eventually lead to cervical cancer.
The current Ontario test combines HPV screening with reflex cytology. The laboratory first tests the sample for high-risk HPV. When indicated by the HPV result, the same sample is examined for abnormal cervical cells without requiring the patient to return immediately for another collection. This approach helps identify people who require closer follow-up while allowing those at very low risk to screen less frequently.
HPV testing is more sensitive than cytology alone for identifying people at risk of developing cervical precancer. This improved ability to rule out significant risk is why most immunocompetent people with an HPV-negative result can safely wait five years before routine screening. By comparison, the former Pap-based program generally used a three-year interval.
It is important to understand that HPV is extremely common and is not necessarily evidence of recent sexual activity or infidelity. An infection may remain undetectable or inactive for years before appearing on a test. Most HPV infections are controlled by the immune system within approximately one or two years, while persistent high-risk infections require appropriate surveillance.
Who Should Receive Cervical Screening in Ontario?
The Ontario Cervical Screening Program generally recommends screening for people who have a cervix, are at least 25 years old and have ever been sexually active. Sexual activity includes genital skin-to-skin contact and does not necessarily require penetrative intercourse. Screening applies to cisgender women, transgender men and non-binary people who retain a cervix.
For most people at average risk, routine screening begins at age 25. Screening before this age is usually unnecessary because HPV infections and minor cervical cell changes are common in younger adults and frequently resolve without intervention. Unnecessary testing may lead to anxiety, repeated procedures and treatment of changes that might otherwise disappear naturally.
Most people with a negative HPV screening result can repeat the test in five years. Those who are immunocompromised may require screening every three years, even after a negative result. A weakened immune system can reduce the body’s ability to clear HPV and may increase the likelihood that cervical abnormalities persist. Individual recommendations should be based on medical history and the clinician’s assessment.
Most people can stop routine cervical screening between ages 65 and 69 when they have an adequate history of normal results and no continuing high-risk factors. Reaching a particular age does not automatically mean screening should stop. Patients with previous high-grade abnormalities, cervical cancer, incomplete screening histories or immune suppression may require continued surveillance.
HPV vaccination substantially reduces the risk of infection with several cancer-causing HPV types. However, vaccination does not protect against every high-risk type and does not treat an infection that was already present. People who received the HPV vaccine should therefore continue cervical screening according to Ontario recommendations.
The need for screening after a hysterectomy depends on the type of surgery and the reason it was performed. Someone who had a subtotal hysterectomy still has a cervix and generally remains eligible for screening. A person whose cervix was completely removed may not require routine screening, particularly when there is no history of cervical precancer or cancer. This decision should be confirmed from operative records and medical history.
Routine cervical screening is intended for people without symptoms. Anyone experiencing bleeding after intercourse, bleeding between periods, unexplained bleeding after menopause, persistent watery or blood-stained discharge, or ongoing pelvic pain should arrange a medical assessment. These symptoms do not automatically indicate cancer, but they require diagnostic evaluation rather than waiting for the next screening invitation.
What Happens During an HPV or Pap Screening Appointment?
Cervical screening is usually completed in a medical examination room and commonly takes only a few minutes. Before beginning, the clinician should explain the procedure, review the patient’s relevant history and obtain consent. Patients can ask questions, request a smaller speculum when appropriate, discuss previous discomfort and ask for the examination to stop at any time.
During the examination, the patient lies on an examination table with the knees bent. A lubricated speculum is gently inserted into the vagina so the cervix can be seen. A small brush or collection device is then used to obtain cells from the cervix. For the patient, HPV testing is performed in essentially the same manner as a traditional Pap test.
The collection may create pressure or brief cramping, but it should not cause severe pain. Mild spotting can occur afterward and usually resolves quickly. Patients should tell the clinician immediately if the procedure becomes painful. Vaginal dryness, menopause, pelvic floor tension, anxiety, previous trauma or certain medical conditions can affect comfort and may require a modified approach.
Before the appointment, patients should inform the clinic if they are menstruating, pregnant, experiencing unusual discharge or using vaginal medication. Heavy menstrual bleeding can make sample collection more difficult, although the appointment should not be cancelled without checking with the clinic. Bringing the date and result of the previous screening test can also help the provider confirm whether testing is currently due.
A cervical screening examination is not the same as a complete pelvic examination or sexually transmitted infection test. The HPV screening sample is designed to identify high-risk HPV associated with cervical cancer. It does not routinely test for infections such as chlamydia, gonorrhea, herpes or HIV. Patients who have possible exposure, symptoms or concerns should request separate STI testing.
Emotional comfort is also clinically important. People with a history of sexual trauma, painful examinations or gender dysphoria may benefit from additional time, a support person, careful explanation and greater control over each step. A respectful clinician should discuss positioning, privacy and ways to reduce discomfort rather than treating the examination as a procedure that must simply be endured.
Understanding Results, Follow-Up and Local Access to Care
An HPV-negative result means that the high-risk HPV types included in the test were not detected. For an average-risk person with a functioning immune system, the next routine screening test is usually recommended in five years. The longer interval does not represent reduced care; it reflects the greater accuracy of HPV testing in identifying people at very low near-term risk.
An HPV-positive result means that a high-risk HPV type was detected. It does not mean that the patient has cervical cancer, and it does not establish when the infection was acquired. The laboratory may perform reflex cytology on the same sample to look for cervical cell changes. The HPV type and cytology findings help determine whether monitoring or further examination is needed.
Follow-up may include repeating the cervical screening test after a defined interval or referring the patient for colposcopy. Colposcopy is a closer examination of the cervix using a magnifying instrument. A biopsy may be taken when an area appears abnormal. Ontario recommendations vary according to HPV type, cytology findings, previous results, immune status and prior cervical treatment.
Patients should not assume that no news means a normal result. Before leaving the appointment, ask how results will be communicated, how long reporting usually takes and whom to contact if no notification is received. Keeping personal records of screening dates and follow-up plans can prevent missed testing when patients change clinics or healthcare providers.
Continuity is particularly valuable after an HPV-positive or abnormal cytology result. A family physician in Etobicoke can review the laboratory report, explain the level of risk, arrange follow-up and maintain a record of previous cervical screening. Long-term documentation helps clinicians interpret new results in the context of earlier tests and treatments.
Women who do not currently have a primary care provider may contact a walk-in clinic in Etobicoke to discuss screening access, symptoms or a previously abnormal result. Availability of cervical screening can vary, so patients should confirm that the service is offered and ask whether an appointment is required. Symptomatic patients should clearly describe their symptoms when booking rather than requesting only routine screening.
Conclusion
Ontario’s transition from routine Pap testing to primary HPV screening represents an important improvement in cervical cancer prevention. The modern screening test looks for the high-risk virus responsible for nearly all cervical cancers and uses cervical cytology when additional assessment is required. For most eligible, average-risk people, screening begins at age 25 and an HPV-negative result allows a five-year interval.
An HPV-positive result should be taken seriously, but it should not be interpreted as a cancer diagnosis. Most HPV infections resolve, while appropriate follow-up allows clinicians to identify persistent infections and precancerous changes early. Women should know their most recent result, understand when the next test is due and seek prompt assessment for unusual bleeding, discharge or pelvic symptoms.
Frequently Asked Questions
1. Is Ontario still using Pap tests?
Ontario now uses HPV testing as the primary cervical screening test. When certain high-risk HPV results are found, the laboratory may examine the same sample using cervical cytology, which is the cell-analysis component traditionally associated with a Pap test.
2. At what age should cervical screening begin?
Routine cervical screening in Ontario generally begins at age 25 for people who have a cervix and have ever been sexually active. Individual recommendations may differ for patients with previous cervical abnormalities, immune suppression or other special circumstances.
3. How often should I receive HPV screening?
Most average-risk, immunocompetent people with a negative HPV result can repeat screening in five years. Immunocompromised patients with negative results may be advised to return in three years. Abnormal or HPV-positive results require an individualized schedule.
4. Does an HPV-positive result mean I have cervical cancer?
No. It means that a high-risk HPV type was detected. Most infections do not become cancer. The result may lead to reflex cytology, repeat testing or colposcopy to determine whether abnormal cervical cells are present.
5. Can HPV appear after many years in a relationship?
Yes. HPV may remain inactive or undetectable for an extended period. A positive result cannot reliably identify when the infection was acquired or from whom it came. It should not automatically be interpreted as evidence of recent transmission.
6. Do I need screening after receiving the HPV vaccine?
Yes. HPV vaccines provide strong protection against several important high-risk types, but they do not protect against every type capable of causing cervical cancer. Vaccinated individuals should continue screening according to provincial recommendations.
7. Do I need screening after menopause?
Possibly. Menopause itself is not a reason to stop screening. Most people can stop between ages 65 and 69 when they have an adequate history of negative results and no significant risk factors. A clinician should confirm the appropriate stopping point.
8. Do I need cervical screening after a hysterectomy?
It depends on whether the cervix was removed and whether there is a history of cervical precancer or cancer. People who had a subtotal hysterectomy generally still require screening because the cervix remains.
9. What symptoms require medical assessment?
Bleeding after intercourse, bleeding between menstrual periods, postmenopausal bleeding, persistent abnormal discharge and unexplained pelvic pain should be assessed. Routine HPV screening is not a substitute for diagnostic evaluation when symptoms are present.
10. Can cervical screening test for other sexually transmitted infections?
No. Cervical HPV screening identifies high-risk HPV associated with cervical cancer. Testing for chlamydia, gonorrhea, HIV, syphilis, herpes and other infections requires separate samples or blood tests based on the infection being investigated.